Johannes Zuber, group leader at the Research Institute of Molecular Pathology (IMP) in Vienna, receives the German Cancer Prize 2016 in the category of experimental cancer research. This was announced today at the opening ceremony of the German Cancer Congress in Berlin.
The German Cancer Prize (Deutscher Krebspreis) is one of the most prestigious scientific awards in the German speaking world and annually honours researchers for groundbreaking discoveries in the field of oncology.
This year's award acknowledges the achievements of Johannes Zuber, whose contributions have shaped the field of functional cancer genetics. Together with his team at the IMP, the physician scientist uses innovative genetic approaches to identify and study genes that are required for the survival of cancer cells and serve as candidate targets for the development of new cancer therapies.
Through developing and applying optimised RNAi-screening methods, Zuber discovered the gene BRD4 as a genetic vulnerability and candidate target for the treatment of acute myeloid leukemia (AML), an aggressive form of blood cancer.
After BRD4 inhibitors have already shown promising effects in AML and other malignancies, his research team could recently identify molecular mechanisms that render leukemia cells resistant to these agents. These insights are of great importance for the future development of BRD4 inhibitors in the clinic.
“This award is a great honour and encouragement to further expand our research in the field of functional cancer genetics”, says Johannes Zuber. He points out that new genetic tools offer fascinating opportunities for finding and probing therapeutic targets such as BRD4: “We are currently witnessing a true revolution in functional genetics, which will enable us to search for better cancer therapies in entirely new ways.”
Johannes Zuber, born 1974 in Dresden, completed his medical studies and a doctoral thesis in molecular cancer research at Berlin’s Charité Medical School in 2003. During his residency in hematology/oncology at the Charité University Hospital, leukemia became the focus of his scientific interest. In 2005, Zuber moved to the US to join Scott Lowe's lab at the renowned Cold Spring Harbor Laboratory, where he developed innovative genetic models to study targeted therapies in leukemia. In 2011, he founded his own lab at the IMP in Vienna.
The German Cancer Prize is endowed with 22,500 Euros and awarded annually by the “Deutsche Krebsgesellschaft” (German Cancer Society) and the “Deutsche Krebsstiftung” (German Cancer Foundation) for groundbreaking work in three categories: experimental research, translational research and clinical research in oncology.
The criteria are exceptional scientific quality and originality of research in the field of oncology. Former awardees include renowned scientists such as Nobel laureate Harald zur Hausen, Peter Krammer, Axel Ullrich or Walter Birchmeier. Johannes Zuber is the first recipient who is affiliated with an institution in Austria.
About the IMP
The Research Institute of Molecular Pathology (IMP) in Vienna is a basic biomedical research institute largely sponsored by Boehringer Ingelheim. With over 200 scientists from 37 nations, the IMP is committed to scientific discovery of fundamental molecular and cellular mechanisms underlying complex biological phenomena. Research areas include cell and molecular biology, neurobiology, disease mechanisms and computational biology.
Media Contact at the IMP
Dr. Heidemarie Hurtl
Research Institute of Molecular Pathology
Dr. Bohr-Gasse 7
A 1030 Vienna
+43 (0)1 79730 3625
Dr. Heidemarie Hurtl | idw - Informationsdienst Wissenschaft
Yuan Chang and Patrick Moore win prize for the discovery of two cancer viruses
14.03.2017 | Goethe-Universität Frankfurt am Main
BMBF funding for diabetes research on pancreas chip
08.02.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
23.03.2017 | Life Sciences
23.03.2017 | Physics and Astronomy
23.03.2017 | Physics and Astronomy